Skip to main content
. Author manuscript; available in PMC: 2022 Feb 1.
Published in final edited form as: Biol Psychiatry Cogn Neurosci Neuroimaging. 2020 Oct 24;6(2):178–187. doi: 10.1016/j.bpsc.2020.10.010

Figure 1. Simulated Clinical High Risk P300 Z-score Data Across Clinical Outcome Sub-Groups.

Figure 1.

Simulated data presented here involve a hypothetical scenario in which the baseline biomarker (e.g., P300 z-score) does not differ between CHR-Remitter and CHR-Persistent subgroups but can predict future CHR-Converter status. Plots in the top row show hypothetical subgroup means and standard deviations when the CHR-Converter subgroup is drawn from the bottom 85%, 65%, 45%, and 30% of the normally distributed CHR simulation samples. Plots in the bottom row collapse the CHR-Persistent and CHR-Converter groups into a single CHR-Non-remitter group, showing that the progressively greater CHR-Remitter versus CHR-Non-remitter effect size is driven entirely by the increasing biomarker deficit in the CHR-Converters.